Anemo Labs is developing an electronic nose that combines sensor technology and AI to detect disease-related compounds through smell, with an initial focus on non-invasive healthcare screening.
Anemo Labs has raised €816k across 1 funding round from 3 investors, most recently a Pre-Seed round in Sep 2026. Based in London, UK; active in AI. Data as of 9 Sept 2026.
Timing: too soon vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2026-09-09 | Pre-Seed | €816k |
| Zinc,Innovate UK,SFC Capital |
| View deal → |
